Aliakbar Saber Moghaddam; Mahdi Hashemi; Ramin Daneshvar
Abstract
Introduction: Intraocular pressure (IOP) can be influenced by several factors including corneal thickness, gender, refractive error, and the presence of diabetes mellitus. In the present study, we systematically reviewed published literature to find association between variations of IOP due to strabismus ...
Read More
Introduction: Intraocular pressure (IOP) can be influenced by several factors including corneal thickness, gender, refractive error, and the presence of diabetes mellitus. In the present study, we systematically reviewed published literature to find association between variations of IOP due to strabismus surgery.Method: PubMed and Scopus were systematically searched with the following search terms: (intraocular pressure OR IOP) AND (strabismus) for the articles in which the fluctuation of IOP before and after strabismus surgery had been evaluated. All types of articles including case series, cross-sectional, clinical trials, and cohort studies with no time limitation were included in this study. Systematically searches, selection of articles, and the extraction of data were performed by two reviewers independently.Result: 1617 out of 1674 articles were excluded due to duplication or irrelevancy. After step by step process of article selection, 57 relevant articles were included for further evaluation. However, only 8 articles met the inclusion criteria.Conclusions: The results of this report showed that IOP may vary due to strabismus surgery, and it decreases after the surgery.
Ali Dehghani; Habib Jafari; Naser Shoeibi
Abstract
Intravitreal injections of anti-vascular endothelial growth factors (anti-VEGFs) have become more popular quickly in recent years. Bevacizumab is an anti- vascular endothelial growth factor agent (anti-VEGF) used to treat choroidal neovascularization and retinal vascular disorders. Rare long lasting ...
Read More
Intravitreal injections of anti-vascular endothelial growth factors (anti-VEGFs) have become more popular quickly in recent years. Bevacizumab is an anti- vascular endothelial growth factor agent (anti-VEGF) used to treat choroidal neovascularization and retinal vascular disorders. Rare long lasting ocular adverse events are reported in the intravitreal injection of this drug that include intraocular inflammation, retinal tears, vitreous hemorrhage, endophtalmitis, and lens changes. One important concern about intravitreal injection of anti-VEGF drug is intraocular pressure (IOP) elevation. There are two kinds of IOP elevation. First one is an acute elevation of IOP (after few minutes) and the second is delayed IOP elevation (after few months). The prevalence of IOP elevation immediately after injection is significantly high and seems to have the potential risk for optic nerve fiber loss results in decreased vision but fortunately this IOP elevation seems to be transient in most of studies.